Cargando…
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging vaccines and antibody therapeutics. Here, we demonstrate that the immunodominant SARS-CoV-2 spike (S) receptor binding motif (RBM) is a highly variable region of S and provide epidemiological, clinical, and molecula...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cell Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843029/ https://www.ncbi.nlm.nih.gov/pubmed/33621484 http://dx.doi.org/10.1016/j.cell.2021.01.037 |
_version_ | 1783644062965825536 |
---|---|
author | Thomson, Emma C. Rosen, Laura E. Shepherd, James G. Spreafico, Roberto da Silva Filipe, Ana Wojcechowskyj, Jason A. Davis, Chris Piccoli, Luca Pascall, David J. Dillen, Josh Lytras, Spyros Czudnochowski, Nadine Shah, Rajiv Meury, Marcel Jesudason, Natasha De Marco, Anna Li, Kathy Bassi, Jessica O’Toole, Aine Pinto, Dora Colquhoun, Rachel M. Culap, Katja Jackson, Ben Zatta, Fabrizia Rambaut, Andrew Jaconi, Stefano Sreenu, Vattipally B. Nix, Jay Zhang, Ivy Jarrett, Ruth F. Glass, William G. Beltramello, Martina Nomikou, Kyriaki Pizzuto, Matteo Tong, Lily Cameroni, Elisabetta Croll, Tristan I. Johnson, Natasha Di Iulio, Julia Wickenhagen, Arthur Ceschi, Alessandro Harbison, Aoife M. Mair, Daniel Ferrari, Paolo Smollett, Katherine Sallusto, Federica Carmichael, Stephen Garzoni, Christian Nichols, Jenna Galli, Massimo Hughes, Joseph Riva, Agostino Ho, Antonia Schiuma, Marco Semple, Malcolm G. Openshaw, Peter J.M. Fadda, Elisa Baillie, J. Kenneth Chodera, John D. Rihn, Suzannah J. Lycett, Samantha J. Virgin, Herbert W. Telenti, Amalio Corti, Davide Robertson, David L. Snell, Gyorgy |
author_facet | Thomson, Emma C. Rosen, Laura E. Shepherd, James G. Spreafico, Roberto da Silva Filipe, Ana Wojcechowskyj, Jason A. Davis, Chris Piccoli, Luca Pascall, David J. Dillen, Josh Lytras, Spyros Czudnochowski, Nadine Shah, Rajiv Meury, Marcel Jesudason, Natasha De Marco, Anna Li, Kathy Bassi, Jessica O’Toole, Aine Pinto, Dora Colquhoun, Rachel M. Culap, Katja Jackson, Ben Zatta, Fabrizia Rambaut, Andrew Jaconi, Stefano Sreenu, Vattipally B. Nix, Jay Zhang, Ivy Jarrett, Ruth F. Glass, William G. Beltramello, Martina Nomikou, Kyriaki Pizzuto, Matteo Tong, Lily Cameroni, Elisabetta Croll, Tristan I. Johnson, Natasha Di Iulio, Julia Wickenhagen, Arthur Ceschi, Alessandro Harbison, Aoife M. Mair, Daniel Ferrari, Paolo Smollett, Katherine Sallusto, Federica Carmichael, Stephen Garzoni, Christian Nichols, Jenna Galli, Massimo Hughes, Joseph Riva, Agostino Ho, Antonia Schiuma, Marco Semple, Malcolm G. Openshaw, Peter J.M. Fadda, Elisa Baillie, J. Kenneth Chodera, John D. Rihn, Suzannah J. Lycett, Samantha J. Virgin, Herbert W. Telenti, Amalio Corti, Davide Robertson, David L. Snell, Gyorgy |
author_sort | Thomson, Emma C. |
collection | PubMed |
description | SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging vaccines and antibody therapeutics. Here, we demonstrate that the immunodominant SARS-CoV-2 spike (S) receptor binding motif (RBM) is a highly variable region of S and provide epidemiological, clinical, and molecular characterization of a prevalent, sentinel RBM mutation, N439K. We demonstrate N439K S protein has enhanced binding affinity to the hACE2 receptor, and N439K viruses have similar in vitro replication fitness and cause infections with similar clinical outcomes as compared to wild type. We show the N439K mutation confers resistance against several neutralizing monoclonal antibodies, including one authorized for emergency use by the US Food and Drug Administration (FDA), and reduces the activity of some polyclonal sera from persons recovered from infection. Immune evasion mutations that maintain virulence and fitness such as N439K can emerge within SARS-CoV-2 S, highlighting the need for ongoing molecular surveillance to guide development and usage of vaccines and therapeutics. |
format | Online Article Text |
id | pubmed-7843029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cell Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-78430292021-01-29 Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity Thomson, Emma C. Rosen, Laura E. Shepherd, James G. Spreafico, Roberto da Silva Filipe, Ana Wojcechowskyj, Jason A. Davis, Chris Piccoli, Luca Pascall, David J. Dillen, Josh Lytras, Spyros Czudnochowski, Nadine Shah, Rajiv Meury, Marcel Jesudason, Natasha De Marco, Anna Li, Kathy Bassi, Jessica O’Toole, Aine Pinto, Dora Colquhoun, Rachel M. Culap, Katja Jackson, Ben Zatta, Fabrizia Rambaut, Andrew Jaconi, Stefano Sreenu, Vattipally B. Nix, Jay Zhang, Ivy Jarrett, Ruth F. Glass, William G. Beltramello, Martina Nomikou, Kyriaki Pizzuto, Matteo Tong, Lily Cameroni, Elisabetta Croll, Tristan I. Johnson, Natasha Di Iulio, Julia Wickenhagen, Arthur Ceschi, Alessandro Harbison, Aoife M. Mair, Daniel Ferrari, Paolo Smollett, Katherine Sallusto, Federica Carmichael, Stephen Garzoni, Christian Nichols, Jenna Galli, Massimo Hughes, Joseph Riva, Agostino Ho, Antonia Schiuma, Marco Semple, Malcolm G. Openshaw, Peter J.M. Fadda, Elisa Baillie, J. Kenneth Chodera, John D. Rihn, Suzannah J. Lycett, Samantha J. Virgin, Herbert W. Telenti, Amalio Corti, Davide Robertson, David L. Snell, Gyorgy Cell Article SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging vaccines and antibody therapeutics. Here, we demonstrate that the immunodominant SARS-CoV-2 spike (S) receptor binding motif (RBM) is a highly variable region of S and provide epidemiological, clinical, and molecular characterization of a prevalent, sentinel RBM mutation, N439K. We demonstrate N439K S protein has enhanced binding affinity to the hACE2 receptor, and N439K viruses have similar in vitro replication fitness and cause infections with similar clinical outcomes as compared to wild type. We show the N439K mutation confers resistance against several neutralizing monoclonal antibodies, including one authorized for emergency use by the US Food and Drug Administration (FDA), and reduces the activity of some polyclonal sera from persons recovered from infection. Immune evasion mutations that maintain virulence and fitness such as N439K can emerge within SARS-CoV-2 S, highlighting the need for ongoing molecular surveillance to guide development and usage of vaccines and therapeutics. Cell Press 2021-03-04 /pmc/articles/PMC7843029/ /pubmed/33621484 http://dx.doi.org/10.1016/j.cell.2021.01.037 Text en © 2021 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Thomson, Emma C. Rosen, Laura E. Shepherd, James G. Spreafico, Roberto da Silva Filipe, Ana Wojcechowskyj, Jason A. Davis, Chris Piccoli, Luca Pascall, David J. Dillen, Josh Lytras, Spyros Czudnochowski, Nadine Shah, Rajiv Meury, Marcel Jesudason, Natasha De Marco, Anna Li, Kathy Bassi, Jessica O’Toole, Aine Pinto, Dora Colquhoun, Rachel M. Culap, Katja Jackson, Ben Zatta, Fabrizia Rambaut, Andrew Jaconi, Stefano Sreenu, Vattipally B. Nix, Jay Zhang, Ivy Jarrett, Ruth F. Glass, William G. Beltramello, Martina Nomikou, Kyriaki Pizzuto, Matteo Tong, Lily Cameroni, Elisabetta Croll, Tristan I. Johnson, Natasha Di Iulio, Julia Wickenhagen, Arthur Ceschi, Alessandro Harbison, Aoife M. Mair, Daniel Ferrari, Paolo Smollett, Katherine Sallusto, Federica Carmichael, Stephen Garzoni, Christian Nichols, Jenna Galli, Massimo Hughes, Joseph Riva, Agostino Ho, Antonia Schiuma, Marco Semple, Malcolm G. Openshaw, Peter J.M. Fadda, Elisa Baillie, J. Kenneth Chodera, John D. Rihn, Suzannah J. Lycett, Samantha J. Virgin, Herbert W. Telenti, Amalio Corti, Davide Robertson, David L. Snell, Gyorgy Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity |
title | Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity |
title_full | Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity |
title_fullStr | Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity |
title_full_unstemmed | Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity |
title_short | Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity |
title_sort | circulating sars-cov-2 spike n439k variants maintain fitness while evading antibody-mediated immunity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843029/ https://www.ncbi.nlm.nih.gov/pubmed/33621484 http://dx.doi.org/10.1016/j.cell.2021.01.037 |
work_keys_str_mv | AT thomsonemmac circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT rosenlaurae circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT shepherdjamesg circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT spreaficoroberto circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT dasilvafilipeana circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT wojcechowskyjjasona circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT davischris circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT piccoliluca circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT pascalldavidj circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT dillenjosh circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT lytrasspyros circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT czudnochowskinadine circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT shahrajiv circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT meurymarcel circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT jesudasonnatasha circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT demarcoanna circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT likathy circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT bassijessica circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT otooleaine circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT pintodora circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT colquhounrachelm circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT culapkatja circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT jacksonben circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT zattafabrizia circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT rambautandrew circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT jaconistefano circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT sreenuvattipallyb circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT nixjay circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT zhangivy circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT jarrettruthf circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT glasswilliamg circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT beltramellomartina circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT nomikoukyriaki circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT pizzutomatteo circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT tonglily circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT cameronielisabetta circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT crolltristani circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT johnsonnatasha circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT diiuliojulia circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT wickenhagenarthur circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT ceschialessandro circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT harbisonaoifem circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT mairdaniel circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT ferraripaolo circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT smollettkatherine circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT sallustofederica circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT carmichaelstephen circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT garzonichristian circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT nicholsjenna circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT gallimassimo circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT hughesjoseph circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT rivaagostino circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT hoantonia circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT schiumamarco circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT semplemalcolmg circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT openshawpeterjm circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT faddaelisa circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT bailliejkenneth circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT choderajohnd circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT rihnsuzannahj circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT lycettsamanthaj circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT virginherbertw circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT telentiamalio circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT cortidavide circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT robertsondavidl circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity AT snellgyorgy circulatingsarscov2spiken439kvariantsmaintainfitnesswhileevadingantibodymediatedimmunity |